Review of the safety, efficacy and tolerability of Palivizumab in the prevention of severe respiratory Syncytial Virus (RSV) disease

Shaun O'Hagan; Niamh C  Galway; Michael D. Shields; Peter Mallett; Helen Groves

doi:10.2147/DHPS.S348727

Review of the safety, efficacy and tolerability of Palivizumab in the prevention of severe respiratory Syncytial Virus (RSV) disease

Shaun O'Hagan, Niamh C Galway, Michael D. Shields, Peter Mallett, Helen Groves^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

9 Citations (Scopus)

27 Downloads (Pure)

Abstract

Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific “high-risk” populations, including congenital heart disease, bronchopulmonary dysplasia and prematurity. Available research suggests palivizumab use in these high-risk populations can lead to a reduction in RSV-related hospitalization. However, palivizumab has not been demonstrated to reduce mortality, adverse events or length of hospital stay related to RSV. In this article, we review the management of RSV, indications for palivizumab prophylaxis, the safety, cost-effectiveness and efficacy of this preventative medication, and emerging therapeutics that could revolutionize future prevention of this significant pathogen.

Original language	English
Pages (from-to)	103-112
Number of pages	10
Journal	Drug, Healthcare and Patient Safety
Volume	15
Early online date	11 Sept 2023
DOIs	https://doi.org/10.2147/DHPS.S348727
Publication status	Published - 11 Sept 2023

Bibliographical note

Funding Information:
HEG previously received honoraria for presenting at an RSV-educational event sponsored by an AstraZeneca Educational grant and for presenting at an RSV-educational event sponsored by AbbVie. MS reports personal fees from Sanofi Pharmaceutical, outside the submitted work. All other authors declare no conflicts of interest in this work.

Publisher Copyright:
© 2023 O’Hagan et al. This work is published and licensed by Dove Medical Press Limited.

Keywords

efficacy
future directions
palivizumab
RSV
safety

ASJC Scopus subject areas

Pharmacology
Health Policy

Access to Document

10.2147/DHPS.S348727Licence: CC BY-NC

Review of the safety, efficacy and tolerability of Palivizumab in the prevention of severe respiratory Syncytial Virus (RSV) disease
© 2023 The Authors. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Final published version, 574 KBLicence: CC BY-NC

Cite this

@article{fdcaa5fa550748488d6d9e5db784e99b,

title = "Review of the safety, efficacy and tolerability of Palivizumab in the prevention of severe respiratory Syncytial Virus (RSV) disease",

abstract = "Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific “high-risk” populations, including congenital heart disease, bronchopulmonary dysplasia and prematurity. Available research suggests palivizumab use in these high-risk populations can lead to a reduction in RSV-related hospitalization. However, palivizumab has not been demonstrated to reduce mortality, adverse events or length of hospital stay related to RSV. In this article, we review the management of RSV, indications for palivizumab prophylaxis, the safety, cost-effectiveness and efficacy of this preventative medication, and emerging therapeutics that could revolutionize future prevention of this significant pathogen.",

keywords = "efficacy, future directions, palivizumab, RSV, safety",

author = "Shaun O'Hagan and Galway, {Niamh C} and Shields, {Michael D.} and Peter Mallett and Helen Groves",

note = "Funding Information: HEG previously received honoraria for presenting at an RSV-educational event sponsored by an AstraZeneca Educational grant and for presenting at an RSV-educational event sponsored by AbbVie. MS reports personal fees from Sanofi Pharmaceutical, outside the submitted work. All other authors declare no conflicts of interest in this work. Publisher Copyright: {\textcopyright} 2023 O{\textquoteright}Hagan et al. This work is published and licensed by Dove Medical Press Limited.",

year = "2023",

month = sep,

day = "11",

doi = "10.2147/DHPS.S348727",

language = "English",

volume = "15",

pages = "103--112",

journal = "Drug, Healthcare and Patient Safety",

issn = "1179-1365",

publisher = "Dove Medical Press Limited",

}

TY - JOUR

T1 - Review of the safety, efficacy and tolerability of Palivizumab in the prevention of severe respiratory Syncytial Virus (RSV) disease

AU - O'Hagan, Shaun

AU - Galway, Niamh C

AU - Shields, Michael D.

AU - Mallett, Peter

AU - Groves, Helen

N1 - Funding Information: HEG previously received honoraria for presenting at an RSV-educational event sponsored by an AstraZeneca Educational grant and for presenting at an RSV-educational event sponsored by AbbVie. MS reports personal fees from Sanofi Pharmaceutical, outside the submitted work. All other authors declare no conflicts of interest in this work. Publisher Copyright: © 2023 O’Hagan et al. This work is published and licensed by Dove Medical Press Limited.

PY - 2023/9/11

Y1 - 2023/9/11

N2 - Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific “high-risk” populations, including congenital heart disease, bronchopulmonary dysplasia and prematurity. Available research suggests palivizumab use in these high-risk populations can lead to a reduction in RSV-related hospitalization. However, palivizumab has not been demonstrated to reduce mortality, adverse events or length of hospital stay related to RSV. In this article, we review the management of RSV, indications for palivizumab prophylaxis, the safety, cost-effectiveness and efficacy of this preventative medication, and emerging therapeutics that could revolutionize future prevention of this significant pathogen.

AB - Respiratory Syncytial Virus (RSV) is a major global cause of childhood morbidity and mortality. Palivizumab, a monoclonal antibody that provides passive immunity against RSV, is currently licensed for prophylactic use in specific “high-risk” populations, including congenital heart disease, bronchopulmonary dysplasia and prematurity. Available research suggests palivizumab use in these high-risk populations can lead to a reduction in RSV-related hospitalization. However, palivizumab has not been demonstrated to reduce mortality, adverse events or length of hospital stay related to RSV. In this article, we review the management of RSV, indications for palivizumab prophylaxis, the safety, cost-effectiveness and efficacy of this preventative medication, and emerging therapeutics that could revolutionize future prevention of this significant pathogen.

KW - efficacy

KW - future directions

KW - palivizumab

KW - RSV

KW - safety

U2 - 10.2147/DHPS.S348727

DO - 10.2147/DHPS.S348727

M3 - Review article

AN - SCOPUS:85171751001

SN - 1179-1365

VL - 15

SP - 103

EP - 112

JO - Drug, Healthcare and Patient Safety

JF - Drug, Healthcare and Patient Safety

ER -

Review of the safety, efficacy and tolerability of Palivizumab in the prevention of severe respiratory Syncytial Virus (RSV) disease

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this